The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Khadzieva Kh.I.

Rostov State Medical University

Chernikova I.V.

Rostov State Medical University

Milyutina N.P.

Southern Federal University

Plotnikov A.A.

Southern Federal University

Clinical and biochemical heterogeneity of Parkinson’s disease

Authors:

Khadzieva Kh.I., Chernikova I.V., Milyutina N.P., Plotnikov A.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(12): 80‑85

DOI: 10.17116/jnevro202012012180

Read: 2505 times

Download PDF (RU)
Contact the author
Table of contents

CLINICAL AND BIOCHEMICAL HETEROGENEITY OF PARKINSON’S DISEASE
CLINICAL AND BIOCHEMICAL HETEROGENEITY OF PARKINSON’S DISEASE

To cite this article:

Khadzieva KhI, Chernikova IV, Milyutina NP, Plotnikov AA. Clinical and biochemical heterogeneity of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(12):80‑85. (In Russ.)
https://doi.org/10.17116/jnevro202012012180

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Art and creativity in Parkinson’s disease: the mysterious effe­cts of dopa­mine. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):13-20
Correlation of motor symptoms and cardiovascular dysfunction in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):59-67
Diagnosis of pathological and adaptive bala­nce changes in Parkinson’s disease to select a reha­bilitation program. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):88-94
The main mechanisms of deve­lopment of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18
Sleep diso­rders in patients with Lewy body deme­ntia and Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):81-87
Therapeutic pote­ntial of quercetin and its deri­vatives against COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):44-50
Effect of uric acid on the progression of Parkinson’s disease: Myth or reality?. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):7-14
Rela­tionship between oxidative stress patterns and proinflammatory cyto­kines in patients with poly­pous rhinosinusitis under the course of therapeutic physical factors. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2025;(2):42-49
Asso­ciations of gene­tic poly­morphisms in key inflammatory response genes with the risk of chro­nic apical periodontitis deve­lopment. Russian Journal of Stomatology. 2025;(2):52-56
Pote­ntial and prospects of the astragaloside IV use for age-associated diseases prevention. Russian Journal of Preventive Medi­cine. 2025;(7):94-99
Abstract:

OBJECTIVE

To study correlations between oxidative stress (OS) and clinical changes in patients with neurodegenerative Parkinson’s and to identify clinical/biochemical subtypes of the disease.

MATERIAL AND METHODS

One hundred and nine people were studied, including 91 patients with neurodegenerative Parkinson’s (72 patients with Parkinson’s disease (PD); 10 with multiple system atrophy (MSA); 9 with corticobasal degeneration (CBD), average age 61.1±7.2 years), and 18 clinically healthy people (average age 55.1±9.2). OS indexes were detected for scoring of redox state in peripheral blood of patients with PD and healthy people (control group). Detection of biochemical indexes was performed in erythrocytes and mononuclear fraction and blood. The activity of glutathione reductase (GR), myeloperoxidase (MPO) and content of reduced glutathione (GSH) was estimated.

RESULTS AND CONCLUSIONS

OS is a universal mechanism and is observed in many neurodegenerative diseases. However it is possible to identify quite typical changes of redox state with group selection and their correlations with definite subtypes and PD progress, it gives opportunity, in particular, to make the differential diagnosis with atypical Parkinsonism.

Keywords:

Parkinson’s disease
oxidative stress
heterogeneity

Authors:

Khadzieva Kh.I.

Rostov State Medical University

Chernikova I.V.

Rostov State Medical University

Milyutina N.P.

Southern Federal University

Plotnikov A.A.

Southern Federal University

Received:

12.02.2020

Accepted:

10.04.2020

Close metadata

References:

  1. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of Aging. 2003;24(2):197-211.  https://doi.org/10.1016/s0197-4580(02)00065-9
  2. Levin OS, Fedorova NV. Parkinson’s disease. Moscow: MEDpress-inform; 2015. (In Russ.).
  3. Kim WS, Kagedal K, Halliday GM. Alpha-synuclein biology in Lewy body diseases. Alzheimers Res Ther. 2014;6(5):73.  https://doi.org/10.1186/s13195-014-0073-2
  4. Foguem C, Manckoundia P. Lewy Body Disease: Clinical and Pathological «Overlap Syndrome» Between Synucleinopathies (Parkinson Disease) and Tauopathies (Alzheimer Disease). Curr Neurol Neurosci Rep. 2018;18(5): 24-33.  https://doi.org/10.1007/s11910-018-0835-5
  5. Subramaniam RS, Chesselet M-F. Mitochondrial dysfunction and oxidative stress in Parkinson’s disease. Prog Neurobiol. 2013;17-32.  https://doi.org/10.1016/j.pneurobio.2013.106-107:04.004
  6. Kovalenko VR, Khabarova EA, Rzaev DA, Medvedev SP. Cellular models, genomic technologies and clinical practice: a synthesis of knowledge for the study of the mechanisms, diagnostics and treatment of Parkinson’s disease. Genes and Cells. 2017;12(2):11-28. (In Russ.). https://doi.org/10.23868/201707012
  7. Hwang O. Role of Oxidative Stress in Parkinson’s Disease. Exp Neurobiol. 2013;22:(1):11-17. (In Russ.).
  8. Fedorova TN, Logvinenko AA, Poleshuk VV, Illarioshkin SN. The State of Systemic Oxidative Stress during Parkinson’s Disease. Neurochemistry. 2017;34(4):344-349. (In Russ.). https://doi.org/10.7868/S1027813317040033
  9. Graciun EC, Dronca E, Leach NV. Antioxidant enzymes activity in subjects with Parkinson’s disease under L-DOPA therapy. Human & Veterinary Medicine. 2016;8:(2):124-127. (In Russ.).
  10. Naduthota RM, Bharath RD, Jhunjhunwala K, et al. Imaging biomarker correlates with oxidative stress in Parkinson’s disease. Neurol India. 2017;65(2):263-268. 
  11. Tapias V. Mitochondrial Dysfunction and Neurodegeneration. Front Neurosci. 2019;13:1372. https://doi.org/10.3389/fnins.2019.01372
  12. Kaur R, Mehan S, Singh Sh. Understanding multifactorial architecture of Parkinson’s disease: pathophysiology to management. Neurol Sci. 2019;40:13-23. 
  13. Kaidery NA, Thomas B. Current Perspective of Mitochondrial Biology in Parkinson’s Disease. Neurochemistry International. 2018;117(7):91-113.  https://doi.org/10.1016/j.neuint.2018.03.001
  14. Kurt AJ. Neuropathology of Multiple System Atrophy: New Thoughts About Pathogenesis. Movement Disorders. 2014;29:14.  https://doi.org/10.1002/mds.26052
  15. Hoehn M, Yahr M. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427-442.  https://doi.org/10.1212/wnl.17.5.427
  16. Unified Parkinson’s Disease Rating Scale (UPDRS) [Internet]. Parkinson’s UK; Feb 5, 2020. Accessed Des 4, 2020. https://www.parkinsons.org.uk/professionals/resources/unified-parkinsons-disease-rating-scale-updrs
  17. Folstein MF, Folstein SE, McHugh PR. «Mini-mental state». A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.  https://doi.org/10.1016/0022-3956(75)90026-6
  18. Sunderland T, Hill J, Mellow AM, et al. J Am Geriatr Soc. 1989;37(8):725-729.  https://doi.org/10.1111/j.1532-5415.1989.tb02233.x
  19. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000;55(11):1621-1626. https://doi.org/10.1212/wnl.55.11.1621
  20. https://www.parkinsonizm.ru/?page=26  https://www.parkinsonizm.ru/?page=26
  21. Zakharov VV, Voznesenskaya TG. Nervno-psikhicheskie narusheniya. Diagnosticheskie testy. Moscow: MEDpress-inform; 2013. p. 257-260. (In Russ.).
  22. Hamilton M. A rating scale for depression. J Neural Neurosurg Psychiatry. 1960;23(1):56-62.  https://doi.org/10.1136/jnnp.23.1.56
  23. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540-545.  https://doi.org/10.1093/sleep/14.6.540
  24. Chaudhuri K, Pal S, Di Marco A, et al. The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2002;73(6):629-635.  https://doi.org/10.1136/jnnp.73.6.629
  25. Postuma RB, Arnulf I, Hogl B, et al. A single-question screen for rapid eye movement sleep behavior disorder: a multicenter validation study. Mov Disord. 2012;27(7):913-916.  https://doi.org/10.1002/mds.25037
  26. Guo JD, Zhao X, Li Y, Liu XL. Damage to dopaminergic neurons by oxidative stress in Parkinson’s disease (Review). Int J Mol Med. 2018;41(4):1817-1825. https://doi.org/10.3892/ijmm.2018.3406
  27. Wei Z, Li X, Li X, et al. Oxidative Stress in Parkinson’s Disease: A Systematic Review and Meta-Analysis. Front Mol Neurosci. 2018;11:236.  https://doi.org/10.3389/fnmol.2018.00236
  28. Vasenina EE, Levin OS. Oxidizing stress in patogeneza of neurodegenerate diseases: possibilities of therapy. Modern Therapy in Psychiatry and Neurology. 2013;(3-4):39-46. (In Russ.).
  29. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968;97:77-89. 
  30. Ellman QL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82(1):70-77.  https://doi.org/10.1016/0003-9861(59)90090-6
  31. Deponte M. Glutathione catalysis and the reaction mechanisms of glutathione-dependent enzymes. Biochim Biophys Acta. 2013;1830(5):3217-3266. https://doi.org/10.1016/j.bbagen.2012.09.018
  32. Mischley LK, Standish LJ, Weiss NS, et al. Glutathione as a Biomarker in Parkinson’s Disease: Associations with Aging and Disease Severity. Oxidative Medicine and Cellular Longevity. 2016;2016:9409363. https://doi.org/10.1155/2016/9409363
  33. Cha SJ, Kim H, Choi H-J, et al. Protein Glutathionylation in the Pathogenesis of Neurodegenerative Diseases. Oxid Med Cell Longev. 2017;2017:2818565. https://doi.org/10.1155/2017/2818565
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.